The U.S. Food and Drug Administration approved dupilumab for eosinophilic esophagitis in patients 12 and up in May 2022. This… Read more »
Tag: dupilumab
Dupilumab Shows Success in EoE, Leading to Hopes for Approval
EoE patients on the biologic drug dupilumab in a Phase 3 trial showed significant symptom improvement by six months of… Read more »
Can a Biologic Drug Teach the Body to Forget Peanut Allergy?
A monoclonal antibody halted the production of peanut-specific IgE in peanut-allergic mice and in blood samples from people with peanut… Read more »
AAAAI News: Dupilumab Remission; Tezepelumab in Severe Asthma; Palforzia Safety
Dupilumab Led to Asthma Remission for Some About 30 percent of patients taking the biologic drug dupilumab experienced “remission” of… Read more »
Allergy News: Dupilumab in Asthma and EoE, Targeted Asthma Inhalers
Dupilumab Reduced Severe Asthma in Children The biologic drug dupilumab markedly improved lung function while also reducing severe asthma attacks… Read more »
FDA Approves “Life-Changing” Biologic Drug Dupilumab for Adolescents with Severe Eczema
Painful, red eczema patches used to run up and down Benjamin Sun’s arms and legs. This severe atopic dermatitis led… Read more »
Ideas Abound in the Eczema Treatment Pipeline
Julie Block says “hope has never been brighter” for atopic dermatitis, better known as eczema. The executive director of the… Read more »
Breakthrough Therapy Changing the Lives of Those With Eczema
A physician and a new biologic drug have been freeing eczema patients of endless itch. Since this article first appeared… Read more »
Hope for Eczema Drug Ranges From Asthma to Food Allergies
This is a sidebar to Allergic Living’s feature: Breakthrough Therapy Changing the Lives of Those Living With Eczema. Dupilumab is… Read more »
Novel Eczema Drug Giving Patients New Lease On Life
New York researchers at Mount Sinai are easing the relentless itch of eczema with a new drug. Dubbed a “breakthrough” therapy by the FDA, it treats eczema’s source rather than just its symptoms.